- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Water Up! at Home
- Behavioral
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 775
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
- Interventions
- AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Device · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Adolescent Substance Use
- Interventions
- Guiding Good Choices
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 11 Years to 12 Years
- Enrollment
- 3,636 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Oakland, California • Aurora, Colorado • Detroit, Michigan
- Conditions
- Facial Rejuvenation With Neurotoxins and/or Hyaluronic Acid Fillers
- Interventions
- Basic Skin Care, Active Skin Care
- Other
- Lead sponsor
- DeNova Research
- Other
- Eligibility
- 21 Years to 60 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Tuberculosis
- Interventions
- BCG strain Connaught, BCG strain Danish, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
- Interventions
- CARv3-TEAM-E T cells
- Drug
- Lead sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension
- Interventions
- Oral Antioxidant, Exercise rehabilitation
- Dietary Supplement · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Asthma
- Interventions
- CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP)
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 134
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 497 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 57
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
- Conditions
- Dermatitis, Atopic
- Interventions
- MK-6194, Placebo
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
- Interventions
- Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Eating Disorders (Excluding Anorexia Nervosa), Binge-Eating Disorder
- Interventions
- Building Healthy Eating and Self-Esteem Together for University Students, Present-Centered Therapy
- Behavioral
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lawrence, Kansas
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
- Conditions
- Acute Myocardial Infarction, Acute Coronary Syndrome, Stable Angina Pectoris, Percutaneous Coronary Intervention, Heart Failure
- Interventions
- Center-Based Cardiac Rehab, mHealth, Home-Based Cardiac Rehab
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Rochester, Minnesota
- Conditions
- Tobacco Dependence
- Interventions
- Nicotine-Containing Electronic Cigarette, Non-Nicotine Electronic Cigarette
- Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Attitude of Health Personnel
- Interventions
- One-on-one physician training, Usual training
- Other
- Lead sponsor
- The Reading Hospital and Medical Center
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- West Reading, Pennsylvania
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
- Interventions
- Bleomycin, Brentuximab Vedotin, Dacarbazine, Doxorubicin, Nivolumab, Quality-of-Life Assessment, Vinblastine
- Drug · Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- e-HERO: Ending the HIV Epidemic in Rural Oklahoma
- Behavioral
- Lead sponsor
- Northern Arizona University
- Other
- Eligibility
- 17 Years to 29 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Flagstaff, Arizona
- Conditions
- Chronic Hepatitis C Virus Infection
- Interventions
- telaprevir, VX-222, ribavirin, peginterferon-alfa-2a
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- La Jolla, California • San Francisco, California • Aurora, Colorado + 16 more
- Conditions
- Neoplasms, Breast
- Interventions
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more
- Conditions
- Sickle Cell Disease, Sickle Cell Trait
- Interventions
- CHOICES, eBook
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Vision, Eye Health
- Interventions
- Carotenoid Group, Control (placebo) group
- Dietary Supplement
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 20 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Solid Tumor
- Interventions
- 5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Hepatitis C
- Interventions
- DCV 3DAA FDC, BMS-791325
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more